Korea Investment Partners (KIP) and Tel Aviv-listed biotechnology enterprise Hadasit Bio Holdings Ltd. have backed an $8 million equity investment in Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, at a valuation of approximately $50 million pre-closing.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
